Tekla Life Sciences Investors (HQL) N-PX Annual report of proxy voting record

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB APPROVAL
	OMB Number:  3235-0582
	Expires:  May 31, 2021
	Estimated average burden
	hours per response........7.2

FORM N-PX

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number  811- 06565

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA	02110
(Address of principal executive offices)	(Zip code)

Laura Woodward

Tekla Life Sciences Investors

100 Federal Street, 19^th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant’s telephone number, including area code:  617-772-8500

Date of fiscal year end:  September 30

Date of reporting period:  7/1/20-6/30/21

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

Vote Summary

AC IMMUNE SA

Security	H00263105	Meeting Type	Annual
Ticker Symbol	ACIU	Meeting Date	20-Nov-2020
Record Date	19-Oct-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Carl June as member of the Board of Directors	Management	For	For
2.	If a new agenda item or a new proposal for an existing agenda item is put before the meeting, I/we hereby authorize and instruct the independent proxy to vote as follows:	Management	For	For

ACADIA PHARMACEUTICALS INC.

Security	004225108	Meeting Type	Annual
Ticker Symbol	ACAD	Meeting Date	22-Jun-2021
Record Date	26-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stephen Biggar, MD Ph.D		For	For
	2	Julian C. Baker		For	For
	3	Daniel B. Soland		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.		Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Security	00650F109	Meeting Type	Annual
Ticker Symbol	ADPT	Meeting Date	11-Jun-2021
Record Date	14-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michelle Griffin		For	For
	2	Peter Neupert		For	For
	3	Leslie Trigg		For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.		Management	For	For
3.	To approve, on a non-binding advisory basis, the frequency of future advisory votes on named executive officers’ compensation.		Management	1 Year	For
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For

AFFIMED N.V

Security	N01045108	Meeting Type	Annual
Ticker Symbol	AFMD	Meeting Date	15-Jun-2021
Record Date	18-May-2021

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Adoption of the Statutory Annual Accounts for the financial year 2020.	Management	For	For
4.	Discharge of the managing directors for their management during the financial year 2020.	Management	For	For
5.	Discharge of the supervisory directors for their supervision during the financial year 2020.	Management	For	For
6.	Appointment of Ms. Denise Mueller to the Management Board.	Management	For	For
7A.	Reappointment of Dr. Ulrich Grau as a supervisory director.	Management	For	For
7B.	Reappointment of Dr. Mathieu Simon as a supervisory director.	Management	For	For
7C.	Appointment of Mrs. Uta Kemmerich-Keil as a supervisory director.	Management	For	For
8.	Appointment of the auditor for the financial year 2021.	Management	For	For
9.	Authorization to acquire shares.	Management	For	For

ALEXION PHARMACEUTICALS, INC.

Security	015351109	Meeting Type	Special
Ticker Symbol	ALXN	Meeting Date	11-May-2021
Record Date	30-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger, dated as of December 12, 2020 (as it may be amended from time to time, the “merger agreement”) by and among Alexion, AstraZeneca PLC (“AstraZeneca”), Delta Omega Sub Holdings Inc., a wholly owned subsidiary of AstraZeneca (“Bidco”), Delta Omega Sub Holdings Inc. 1, a direct, wholly owned subsidiary of Bidco and Delta Omega Sub Holdings LLC 2, a direct, wholly owned subsidiary of Bidco (the “merger proposal”).	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Alexion’s named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement.	Management	For	For
3.	To approve the adjournment of the Alexion special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Alexion special meeting to approve the merger proposal or to ensure that any supplement or amendment to this proxy statement/ prospectus is timely provided to Alexion stockholders.	Management	For	For

ALKERMES PLC

Security	G01767105	Meeting Type	Annual
Ticker Symbol	ALKS	Meeting Date	14-Jun-2021
Record Date	19-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: David A. Daglio, Jr.	Management	For	For
1.2	Election of Class I Director: Nancy L. Snyderman, M.D.	Management	For	For
1.3	Election of Class I Director: Frank Anders Wilson	Management	For	For
1.4	Election of Class I Director: Nancy J. Wysenski	Management	For	For
2.	To approve, in a non-binding, advisory vote, the compensation of the Company’s named executive officers.	Management	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration.	Management	For	For
4.	To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.	Management	For	For
5.	To approve certain amendments to the Company’s Articles of Association that would serve to declassify the Board.	Management	For	For

ALLAKOS INC.

Security	01671P100	Meeting Type	Annual
Ticker Symbol	ALLK	Meeting Date	25-May-2021
Record Date	08-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Daniel Janney		For	For
	2	Robert E. Andreatta		For	For
2.	Ratification and approval of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
3.	Approval, on an advisory non-binding basis, of the compensation of the Company’s named executive officers.		Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	18-May-2021
Record Date	29-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director to serve for a term ending in 2024: Dennis A. Ausiello, M.D.	Management	For	For
1B.	Election of Class II Director to serve for a term ending in 2024: Olivier Brandicourt, M.D.	Management	For	For
1C.	Election of Class II Director to serve for a term ending in 2024: Marsha H. Fanucci	Management	For	For
1D.	Election of Class II Director to serve for a term ending in 2024: David E.I. Pyott	Management	For	For
2.	To approve, in a non-binding advisory vote, the compensation of Alnylam’s named executive officers.	Management	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam’s independent auditors for the fiscal year ending December 31, 2021.	Management	For	For

AMARIN CORPORATION PLC

Security	023111206	Meeting Type	Annual
Ticker Symbol	AMRN	Meeting Date	13-Jul-2020
Record Date	22-May-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Dr. Lars G. Ekman as a director.	Management	For	For
2.	To re-elect Mr. Joseph S. Zakrzewski as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company’s “named executive officers” as described in full in the “Executive Compensation Discussion and Analysis” section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure in the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors’ remuneration as described in full in the accompanying Proxy Statement.	Management	For	For
5.	To approve the Amarin Corporation plc 2020 Stock Incentive Plan as described in full in the accompanying Proxy Statement in advance of the expiration of the 2011 Plan.	Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	18-May-2021
Record Date	19-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director for a term of office expiring at the 2022 annual meeting: Dr. Wanda M. Austin	Management	For	For
1B.	Election of Director for a term of office expiring at the 2022 annual meeting: Mr. Robert A. Bradway	Management	For	For
1C.	Election of Director for a term of office expiring at the 2022 annual meeting: Dr. Brian J. Druker	Management	For	For
1D.	Election of Director for a term of office expiring at the 2022 annual meeting: Mr. Robert A. Eckert	Management	For	For
1E.	Election of Director for a term of office expiring at the 2022 annual meeting: Mr. Greg C. Garland	Management	For	For
1F.	Election of Director for a term of office expiring at the 2022 annual meeting: Mr. Charles M. Holley, Jr.	Management	For	For
1G.	Election of Director for a term of office expiring at the 2022 annual meeting: Dr. Tyler Jacks	Management	For	For
1H.	Election of Director for a term of office expiring at the 2022 annual meeting: Ms. Ellen J. Kullman	Management	For	For
1I.	Election of Director for a term of office expiring at the 2022 annual meeting: Ms. Amy E. Miles	Management	For	For
1J.	Election of Director for a term of office expiring at the 2022 annual meeting: Dr. Ronald D. Sugar	Management	For	For
1K.	Election of Director for a term of office expiring at the 2022 annual meeting: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2021.	Management	For	For

AMICUS THERAPEUTICS, INC.

Security	03152W109	Meeting Type	Annual
Ticker Symbol	FOLD	Meeting Date	10-Jun-2021
Record Date	15-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Craig A. Wheeler		For	For
	2	Burke W. Whitman		For	For
2.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool.		Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
4.	Approval, on an advisory basis, the Company’s executive compensation.		Management	For	For

APELLIS PHARMACEUTICALS INC.

Security	03753U106	Meeting Type	Annual
Ticker Symbol	APLS	Meeting Date	01-Jun-2021
Record Date	05-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Paul Fonteyne		For	For
	2	Stephanie M. O’Brien		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
3.	To approve an advisory vote on executive compensation.		Management	For	For

ARCA BIOPHARMA, INC.

Security	00211Y506	Meeting Type	Annual
Ticker Symbol	ABIO	Meeting Date	10-Dec-2020
Record Date	14-Oct-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Dr. Michael R. Bristow		For	For
	2	Mr. Robert E. Conway		For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the Company for its fiscal year ending December 31. 2020.		Management	For	For
3.	To approve the 2020 ARCA Equity Incentive Plan.		Management	Against	Against
4.	To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement.		Management	Against	Against

ARCUTIS BIOTHERAPEUTICS, INC.

Security	03969K108	Meeting Type	Annual
Ticker Symbol	ARQT	Meeting Date	09-Jun-2021
Record Date	13-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director to hold office until the 2024 Annual Meeting: Terrie Curran	Management	For	For
1B.	Election of Class I Director to hold office until the 2024 Annual Meeting: Halley Gilbert	Management	For	For
1C.	Election of Class I Director to hold office until the 2024 Annual Meeting: Ricky Sun, Ph.D.	Management	For	For
2.	To ratify the selection, by the Audit Committee of the Company’s Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.	Management	For	For

ARDELYX, INC.

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	16-Jun-2021
Record Date	20-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	William Bertrand Jr Esq		For	For
	2	Onaiza Cadoret-Manier		For	For
	3	Jan Lundberg, Ph.D.		For	For
2.	To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2021.		Management	For	For
3.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on- Pay”).		Management	For	For

ARENA PHARMACEUTICALS, INC.

Security	040047607	Meeting Type	Annual
Ticker Symbol	ARNA	Meeting Date	11-Jun-2021
Record Date	15-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jayson Dallas, M.D.		For	For
	2	Oliver Fetzer, Ph.D.		For	For
	3	Kieran T. Gallahue		For	For
	4	Jennifer Jarrett		For	For
	5	Katharine Knobil, M.D.		For	For
	6	Amit D. Munshi		For	For
	7	Garry A. Neil, M.D.		For	For
	8	Tina S. Nova, Ph.D.		For	For
	9	Nawal Ouzren		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.		Management	For	For
3.	To approve the Arena Pharmaceuticals, Inc. 2021 Long- Term Incentive Plan.		Management	For	For
4.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2021.		Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	11-May-2021
Record Date	13-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Adoption of the new remuneration policy.	Management	For
4.	Advisory vote to approve the 2020 remuneration report.	Management	For
5B.	Adoption of the 2020 annual accounts.	Management	For
5D.	Allocation of losses of the Company in the financial year 2020 to the retained earnings of the Company.	Management	For
5E.	Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2020.	Management	For
6.	Appointment of Yvonne Greenstreet as non-executive director to the board of directors of the Company.	Management	For
7.	Re-appointment of Anthony Rosenberg as non-executive director to the board of directors of the Company.	Management	For
8.	Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any.	Management	For
9.	Appointment of Deloitte Accountants B.V. as statutory auditor for the 2021 financial year.	Management	For

ARROWHEAD PHARMACEUTICALS, INC.

Security	04280A100	Meeting Type	Annual
Ticker Symbol	ARWR	Meeting Date	18-Mar-2021
Record Date	25-Jan-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Christopher Anzalone		For	For
	2	Marianne De Backer		For	For
	3	Mauro Ferrari		For	For
	4	Douglass Given		For	For
	5	Oye Olukotun		For	For
	6	Michael S. Perry		For	For
	7	William Waddill		For	For
2.	To approve, in an advisory (non-binding) vote, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.		Management	For	For
3.	To approve the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan.		Management	For	For
4.	To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2021.		Management	For	For

ARVINAS, INC.

Security	04335A105	Meeting Type	Annual
Ticker Symbol	ARVN	Meeting Date	08-Jun-2021
Record Date	12-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Wendy Dixon, Ph.D.		For	For
	2	Edward Kennedy, Jr.		For	For
	3	Bradley Margus		For	For
	4	Briggs Morrison, M.D.		For	For
2.	To approve, on an advisory basis, the Company’s named executive compensation.		Management	For	For
3.	To approve, on an advisory basis, the frequency of the advisory vote on executive compensation.		Management	1 Year	For
4.	Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	28-May-2021
Record Date	20-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting.	Management	For	For
2.	Report on the Company’s Activities during the Past Year.	Management	For	For
3.	Presentation of Audited Annual Report with Auditor’s Statement for Approval and Discharge of the Board of Directors and Management.	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report.	Management	For	For
5A.	Election of Board Member for Class I, with a term expiring at the annual general meeting held in 2023: James I. Healy	Management	For	For
5B.	Election of Board Member for Class I, with a term expiring at the annual general meeting held in 2023: Jan MØller Mikkelsen	Management	For	For
5C.	Election of Board Member for Class I, with a term expiring at the annual general meeting held in 2023: Lisa Morrison	Management	For	For
6.	Election of State-authorized Public Auditor.	Management	For	For
7A.	The Board of Directors is authorized to increase the Company’s share capital by up to nominal DKK 9,000,000 without pre-emptive subscription right for the Company’s shareholder. The capital increase must be carried out at market price.	Management	For	For
7B.	The Board of Directors is authorized to issue up to nominal 2,000,000 new warrants to management, employees and consultants. The exercise price of such warrants shall be determined by the Board of Directors and shall equal at least to the market price of the shares at the time of issuance.	Management	For	For
7C.	The Board of Directors is authorized, to purchase up to nominal DKK 2,000,000 shares or American Depositary Shares representing a corresponding amount of shares in the Company as treasury shares. The minimum price per share shall be DKK 1 and the maximum price per share shall not exceed the market price.	Management	For	For

ATRECA INC

Security	04965G109	Meeting Type	Annual
Ticker Symbol	BCEL	Meeting Date	09-Jun-2021
Record Date	15-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Brian Atwood		For	For
	2	W. H. Robinson, M.D PhD		For	For
	3	Tito A. Serafini, Ph.D.		For	For
2.	Ratification of the selection of OUM & Co. LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.		Management	For	For

AURINIA PHARMACEUTICALS INC.

Security	05156V102	Meeting Type	Annual and Special Meeting
Ticker Symbol	AUPH	Meeting Date	07-Jun-2021
Record Date	19-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1	To fix the number of directors to be elected at eight (8).		Management	For	For
2	DIRECTOR		Management
	1	George Milne		For	For
	2	Peter Greenleaf		For	For
	3	David R.W. Jayne		For	For
	4	Joseph P. Hagan		For	For
	5	Daniel Billen		For	For
	6	R. Hector MacKay-Dunn		For	For
	7	Jill Leversage		For	For
	8	Timothy P. Walbert		For	For
3	Appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the 2022 annual general meeting of shareholders or until a successor is appointed. To withhold your vote, mark the against box.		Management	For	For
4	To approve, on a non-binding advisory basis, a “say on pay” resolution regarding the Company’s executive compensation set forth in the Company’s Proxy Statement/Circular.		Management	For	For
5	To approve, on a non-binding advisory basis, the frequency of future advisory votes on “say on pay” as occurring every 1, 2 or 3 years.		Management	1 Year	For
6	To approve the Company’s Amended and Restated Equity Incentive Plan as adopted by the Board as set forth in the Company’s Proxy Statement/Circular.		Management	For	For
7	To approve the 2021 Employee Share Purchase Plan as set forth in the Company’s Proxy Statement/Circular.		Management	For	For
8	To confirm the Company’s Amended and Restated By- law No. 2 to increase the quorum for shareholder meetings to 33 1/3% as adopted by the Board as set forth in the Company’s Proxy Statement/Circular.		Management	For	For

AVADEL PHARMACEUTICALS PLC

Security	05337M104	Meeting Type	Annual
Ticker Symbol	AVDL	Meeting Date	05-Aug-2020
Record Date	27-May-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	By separate resolutions, to elect the following six current Directors: Gregory J. Divis, Dr. Eric J. Ende, Geoffrey M. Glass, Linda S. Palczuk, Dr. Mark A. McCamish and Peter Thornton to the Board of Directors (the “Board”); each to serve a one year term expiring at the conclusion of the next annual general meeting of shareholders (“Proposal 1”).	Management	For	For
2.	To ratify, in a non-binding vote, the appointment of Deloitte & Touche LLP as the Company’s independent registered public auditor and accounting firm for the fiscal year ending December 31, 2020 and to authorize, in a binding vote, the Audit Committee of the Board to set the independent registered public auditor and accounting firm remuneration (“Proposal 2”).	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company (“Proposal 3”).	Management	For	For
4.	To approve the Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan (“Proposal 4”).	Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Special
Ticker Symbol	BGNE	Meeting Date	20-Nov-2020
Record Date	10-Sep-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT the grant of an option to acquire shares to Amgen Inc. (“Amgen”) to allow Amgen to subscribe for additional shares under a specific mandate in an amount necessary to enable it to increase (and subsequently maintain) its ownership at approximately 20.6% of the Company’s outstanding share capital, up to an aggregate of 75,000,000 ordinary shares during the option term, pursuant to the terms of the Restated Amendment No. 2 dated September 24, 2020 to the Share Purchase Agreement ...Due to space limits, see proxy material for full proposal.	Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	16-Jun-2021
Record Date	19-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
O1	THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2024 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O2	THAT Michael Goller be and is hereby re-elected to serve as a Class II director of the Company until the 2024 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O3	THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2024 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O4	THAT Corazon (Corsee) D. Sanders be and is hereby re- elected to serve as a Class II director until the 2024 annual general meeting of the shareholders of the Company and until her successor is duly elected and qualified, subject to her earlier resignation or removal.	Management	For	For
O5	THAT the appointment of Ernst & Young Hua Ming LLP and Ernst & Young as the Company’s independent registered public accounting firms for the fiscal year ending December 31, 2021 be and is hereby approved, ratified and confirmed.	Management	For	For
O6	THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares not exceeding 20% of the total number of issued ordinary shares of the Company as of the date of passing of this ordinary resolution up to the next annual general meeting of the shareholders of the Company be and is hereby approved.	Management	For	For
O7	THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the “Existing Shareholders”), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities.	Management	For	For
O8	THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of the Existing Shareholders, up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share capital of the Company) before and after the proposed issue of shares (the “RMB Shares”) to be listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange.	Management	For	For
O9	THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. (“Amgen”), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then- outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 6 for a period of five years, which period will be subject to an extension on a rolling basis each year.	Management	For	For
O10	THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen, up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the proposed issue of shares to be listed on the STAR Market and to be traded in RMB pursuant to the general mandate set forth in Resolution 6.	Management	For	For
O11	THAT the grant of an option to acquire shares to Amgen to allow Amgen to subscribe for additional shares under a specific mandate in an amount necessary to enable it to increase (and subsequently maintain) its ownership at approximately 20.6% of the Company’s outstanding share capital, up to an aggregate of 75,000,000 ordinary shares during the option term, pursuant to the terms of the Restated Amendment No. 2 dated September 24, 2020 to the Share Purchase Agreement dated October 31, 2019, as amended.	Management	For	For
O12	THAT the grant of the restricted share units (“RSUs”) with a grant date fair value of US$3,750,000 to Mr. John V. Oyler under the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the “2016 Plan”), according to the terms and conditions described in the Proxy Statement, be and is hereby approved.	Management	For	For
O13	THAT the grant of RSUs with a grant date fair value of US$1,000,000 to Dr. Xiaodong Wang under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.	Management	For	For
O14	THAT the grant of the RSUs with a grant date fair value of US$200,000 to each of other non-executive and independent non- executive directors, Mr. Anthony C. Hooper, Mr. Timothy Chen, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Corazon (Corsee) D. Sanders, Mr. Jing- Shyh (Sam) Su and Mr. Qingqing Yi, under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.	Management	For	For
O15	THAT, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.	Management	For	For
S16	THAT the adoption of the Sixth Amended and Restated Memorandum and Articles of Association of the Company, be and is hereby approved, conditioned on and subject to the listing of RMB Shares on the STAR Market.	Management	For	For
O17	THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve any of the proposals described above, and on the reverse side, be and is hereby approved.	Management	For	For

BELLICUM PHARMACEUTICALS, INC.

Security	079481404	Meeting Type	Annual
Ticker Symbol	BLCM	Meeting Date	15-Jun-2021
Record Date	19-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jon P. Stonehouse		For	For
	2	Stephen R. Davis		For	For
2.	To approve an amendment to the Company’s 2019 Equity Incentive Plan to, among other things, increase the number of shares of common stock authorized for issuance thereunder by 500,000 shares.		Management	For	For
3.	To ratify the Audit Committee’s selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.		Management	For	For
4.	To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement.		Management	For	For

BIO-TECHNE CORP

Security	09073M104	Meeting Type	Annual
Ticker Symbol	TECH	Meeting Date	29-Oct-2020
Record Date	03-Sep-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To set the number of Directors at nine.	Management	For	For
2A.	Election of Director: Robert V. Baumgartner	Management	For	For
2B.	Election of Director: Julie L. Bushman	Management	For	For
2C.	Election of Director: John L. Higgins	Management	For	For
2D.	Election of Director: Joseph D. Keegan	Management	For	For
2E.	Election of Director: Charles R. Kummeth	Management	For	For
2F.	Election of Director: Roeland Nusse	Management	For	For
2G.	Election of Director: Alpna Seth	Management	For	For
2H.	Election of Director: Randolph Steer	Management	For	For
2I.	Election of Director: Rupert Vessey	Management	For	For
3.	Cast a non-binding vote on named executive officer compensation.	Management	For	For
4.	Approve an amendment and restatement to the Company’s Second Amended and Restated 2010 Equity Incentive Plan to allocate 1,300,000 additional shares to the Plan reserve and to make certain additional amendments.	Management	For	For
5.	Ratify the appointment of the Company’s independent registered public accounting firm for the 2021 fiscal year.	Management	For	For

BIOTHERYX THERAPEUTICS, INC

Security	N/A	Meeting Type	Annual
Ticker Symbol	N/A	Meeting Date	18-Mar-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Ratification and Election of Directors	Management	For	For
2	General Authorizing Resolution	Management	For	For

BIOGEN INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	02-Jun-2021
Record Date	09-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Alexander J. Denner	Management	For	For
1B.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Caroline D. Dorsa	Management	For	For
1C.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Maria C. Freire	Management	For	For
1D.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: William A. Hawkins	Management	For	For
1E.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: William D. Jones	Management	For	For
1F.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Nancy L. Leaming	Management	For	For
1G.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Jesus B. Mantas	Management	For	For
1H.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Richard C. Mulligan	Management	For	For
1I.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Stelios Papadopoulos	Management	For	For
1J.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Brian S. Posner	Management	For	For
1K.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Eric K. Rowinsky	Management	For	For
1L.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Stephen A. Sherwin	Management	For	For
1M.	Election of Director to serve for a one-year term extending until the 2022 annual meeting: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For
4.	To approve an amendment to Biogen’s Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision.	Management	For	For
5.	Stockholder proposal requesting a report on Biogen’s lobbying activities.	Shareholder	Against	For
6.	Stockholder proposal requesting a report on Biogen’s gender pay gap.	Shareholder	Against	For

BIOMARIN PHARMACEUTICAL INC.

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	25-May-2021
Record Date	29-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jean-Jacques Bienaimé		For	For
	2	Elizabeth M. Anderson		For	For
	3	Willard Dere		For	For
	4	Michael Grey		For	For
	5	Elaine J. Heron		For	For
	6	Maykin Ho		For	For
	7	Robert J. Hombach		For	For
	8	V. Bryan Lawlis		For	For
	9	Richard A. Meier		For	For
	10	David E.I. Pyott		For	For
	11	Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2021.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement.		Management	For	For
4.	To approve an amendment to the 2017 Equity Incentive Plan, as amended.		Management	For	For

BIONTECH SE

Security	09075V102	Meeting Type	Annual
Ticker Symbol	BNTX	Meeting Date	22-Jun-2021
Record Date	13-May-2021

Item	Proposal	Proposed by	Vote	For/Against Management
2	Approval of the actions of the Management Board.	Management	For	For
3	Approval of the actions of the Supervisory Board.	Management	For	For
4	Appointment of the auditor for the financial year 2021.	Management	For	For
5	Resolution on the revocation of the existing authorized capital and the creation of a new authorized capital (Authorized Capital 2021) against contributions in cash and/or in kind with the possibility of excluding subscription rights and corresponding amendments to the Articles of Association.	Management	For	For
6	Amendment of the authorization to issue stock options.	Management	For	For
7	Resolution on the partial revocation and amendment of the current authorization to issue stock options (Stock Option Program 2017/2019) and on the partial revocation of Conditional Capital ESOP 2017/2019; Resolution on the authorization to issue stock options (Stock Option Program 2021) and on the implementation of a new Conditional Capital 2021 and corresponding amendments of the Articles of Association.	Management	For	For
8	Amendment to the existing authorization to acquire treasury shares and their use, also excluding subscription rights.	Management	For	For
9	Extending the authorization to acquire treasury shares and to use them, also excluding subscription rights.	Management	For	For
10	Resolution on the approval of the system for the compensation of the members of the Management Board.	Management	For	For
11	Resolution on the compensation and on the compensation system for the members of the Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association.	Management	For	For
12	Resolution on the revocation of the resolution of the Company’s Annual General Meeting of June 26, 2020 (agenda item 8 lit. d)) on the consent to the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company.	Management	For	For
13A	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company.	Management	For	For
13B	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Manufacturing Marburg GmbH as dependent company.	Management	For	For
13C	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and reSano GmbH as dependent company.	Management	For	For

BLACK DIAMOND THERAPEUTICS, INC.

Security	09203E105	Meeting Type	Annual
Ticker Symbol	BDTX	Meeting Date	18-Jun-2021
Record Date	21-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Alexander Mayweg		For	For
	2	Rajeev Shah		For	For
	3	Robert A. Ingram		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.’s independent registered accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

BLUEPRINT MEDICINES CORPORATION

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	02-Jun-2021
Record Date	09-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	George D. Demetri		For	For
	2	Lynn Seely		For	For
2.	To approve an advisory vote on named executive officer compensation.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

BRIDGEBIO PHARMA INC

Security	10806X102	Meeting Type	Annual
Ticker Symbol	BBIO	Meeting Date	17-Jun-2021
Record Date	07-May-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Eric Aguiar, M.D.		For	For
	2	Ali Satvat		For	For
	3	Jennifer E. Cook		For	For
2.	To cast a non-binding, advisory vote to approve the compensation of the Company’s named executive officers.		Management	For	For
3.	To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of the Company’s named executive officers.		Management	1 Year	For
4.	To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.		Management	For	For

CELLECTIS S.A.

Security	15117K103	Meeting Type	Special
Ticker Symbol	CLLS	Meeting Date	04-Nov-2020
Record Date	06-Oct-2020

Item	Proposal	Proposed by	Vote	For/Against Management
O1	Appointment of Mr. Jean-Pierre Garnier as a new board member.	Management	For	For
E2	Amendment to the age limit applicable to directors, the chief executive officer and deputy chief executive officers.	Management	For	For

CELLECTIS S.A.

Security	15117K103	Meeting Type	Special
Ticker Symbol	CLLS	Meeting Date	04-Nov-2020
Record Date	20-Oct-2020

Item	Proposal	Proposed by	Vote	For/Against Management
O1	Appointment of Mr. Jean-Pierre Garnier as a new board member.	Management	For	For
E2	Amendment to the age limit applicable to directors, the chief executive officer and deputy chief executive officers.	Management	For	For

CHEMOCENTRYX INC

Security	16383L106	Meeting Type	Annual
Ticker Symbol	CCXI	Meeting Date	20-May-2021
Record Date	31-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Thomas J. Schall, Ph.D.	Management	For	For
1B.	Election of Director: Joseph M. Feczko, M.D.	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2021.	Management	For	For
3.	Approval of the amendment and restatement of the 2012 Equity Incentive Award Plan.	Management	For	For
4.	Approval of the amendment and restatement of the 2012 Employee Stock Purchase Plan.	Management	For	For
5.	Approval, on an advisory basis, of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure of the Securities and Exchange Commission.	Management	For	For

CLEARSIDE BIOMEDICAL, INC.

Security	185063104	Meeting Type	Annual
Ticker Symbol	CLSD	Meeting Date	10-Jun-2021
Record Date	19-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Richard Croarkin		For	For
	2	William D. Humphries		For	For
	3	Nancy J. Hutson		For	For
2.	Ratification of the selection of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2021.		Management	For	For

COGENT BIOSCIENCES, INC.

Security	19240Q102	Meeting Type	Special
Ticker Symbol	COGT	Meeting Date	06-Nov-2020
Record Date	09-Oct-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve, in accordance with Nasdaq Listing Rule 5635, the issuance of the Company’s common stock upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, issued in a merger that closed on July 6, 2020 and a private placement offering that closed on July 9, 2020.	Management	For	For
2.	To approve the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the Company’s common stock.	Management	For	For
3.	To consider and vote upon an adjournment or postponement of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1 and/or 2.	Management	For	For

COGENT BIOSCIENCES, INC.

Security	19240Q201	Meeting Type	Annual
Ticker Symbol	COGT	Meeting Date	16-Jun-2021
Record Date	26-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Andrew Robbins		For	For
	2	Peter Harwin		For	For
2.	An amendment and restatement of the 2018 Stock Option and Incentive Plan to increase the number of shares reserved for issuance.		Management	For	For
3.	Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.		Management	For	For

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Security	21833P103	Meeting Type	Annual
Ticker Symbol	CRBP	Meeting Date	17-Jun-2021
Record Date	31-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Yuval Cohen		For	For
	2	Alan Holmer		For	For
	3	Avery W. Catlin		For	For
	4	Peter Salzmann		For	For
	5	John Jenkins		For	For
	6	Rachelle Jacques		For	For
2.	Ratification of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.		Management	For	For
3.	Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers.		Management	For	For
4.	To approve an amendment to the Company’s certificate of incorporation, as amended, to increase the Company’s authorized shares of common stock from 150,000,000 to 300,000,000.		Management	For	For

CRISPR THERAPEUTICS AG

Security	H17182108	Meeting Type	Annual
Ticker Symbol	CRSP	Meeting Date	10-Jun-2021
Record Date	16-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2020.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4a.	Re-election of Rodger Novak, M.D., as member and Chairman.	Management	For	For
4b.	Re-election of Samarth Kulkarni, Ph.D. as the member to the Board of Director.	Management	For	For
4c.	Re-election of Ali Behbahani, M.D. as the member to the Board of Director.	Management	For	For
4d.	Re-election of Bradley Bolzon, Ph.D. as the member to the Board of Director.	Management	For	For
4e.	Re-election of Simeon J. George, M.D. as the member to the Board of Director.	Management	For	For
4f.	Re-election of John T. Greene as the member to the Board of Director.	Management	For	For
4g.	Re-election of Katherine A. High, M.D. as the member to the Board of Director.	Management	For	For
4h.	Re-election of Douglas A. Treco, Ph.D. as the member to the Board of Director.	Management	For	For
4i.	Election of H Edward Fleming Jr., M.D. as the member to the Board of Director.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Ali Behbahani, M.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
5c.	Re-election of the member of the Compensation Committee: John T. Greene	Management	For	For
6a.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2021 Annual General Meeting to the 2022 annual general meeting of shareholders.	Management	For	For
6b.	Binding vote on equity for members of the Board of Directors from the 2021 Annual General Meeting to the 2022 annual general meeting of shareholders.	Management	For	For
6c.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2021 to June 30, 2022.	Management	For	For
6d.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2021.	Management	For	For
6e.	Binding vote on equity for members of the Executive Committee from the 2021 Annual General Meeting to the 2022 annual general meeting of shareholders.	Management	For	For
7.	The approval of an increase in the Conditional Share Capital for Employee Equity Plans.	Management	For	For
8.	The approval of increasing the maximum size of the Board of Directors.	Management	For	For
9.	The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase the share capital.	Management	For	For
10.	The re-election of the independent voting rights representative.	Management	For	For
11.	The re-election of the auditors.	Management	For	For

CURASEN THERAPEUTICS, INC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Nov-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amended and Restated Certificate of Incorporation	Management	For	For
2.	General Authority and Ratification	Management	For	For

CURASEN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Apr-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Waiver of Audited Financial Statements	Management	For	For
2	General Authority and Ratification	Management	For	For

CYMABAY THERAPEUTICS INC

Security	23257D103	Meeting Type	Annual
Ticker Symbol	CBAY	Meeting Date	10-Jun-2021
Record Date	12-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Janet Dorling		For	For
	2	Caroline Loewy		For	For
	3	Sujal Shah		For	For
	4	Kurt von Emster		For	For
	5	Thomas G. Wiggans		For	For
	6	Robert J. Wills		For	For
2.	Ratification of selection, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of CymaBay for its fiscal year ending December 31, 2021.		Management	For	For
3.	Advisory vote to approve the compensation of our named executive officers as disclosed in the proxy statement.		Management	For	For

DECIPHER BIOSCIENCES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	23-Jul-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment of 2018 Equity Incentive Plan	Management	For	For
2.	General Authorizing Resolution	Management	For	For

DECIPHER BIOSCIENCES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	1-Mar-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Merger and Agreement and Plan of Merger	Management	For	For
2.	Waiver of Notice Rquirements	Management	For	For
3.	Waiver of Appraisal Rights	Management	For	For
4.	Termination of Stockholder Agreements	Management	For	For

DECIPHERA PHARMACEUTICALS, INC.

Security	24344T101	Meeting Type	Annual
Ticker Symbol	DCPH	Meeting Date	23-Jun-2021
Record Date	26-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James A. Bristol, Ph.D.		For	For
	2	Frank S. Friedman		For	For
	3	Ron Squarer		For	For
2.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.		Management	For	For
3.	To recommend, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers.		Management	1 Year	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP as Deciphera Pharmaceuticals, Inc.’s independent registered public accounting firm for the year ending December 31, 2021.		Management	For	For

DENALI THERAPEUTICS INC.

Security	24823R105	Meeting Type	Annual
Ticker Symbol	DNLI	Meeting Date	02-Jun-2021
Record Date	12-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Douglas Cole, M.D.		For	For
	2	Jay Flatley		For	For
	3	M Tessier-Lavigne, Ph.D		For	For
	4	Nancy A. Thornberry		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For
3.	Advisory vote on executive compensation.		Management	For	For

DICERNA PHARMACEUTICALS, INC.

Security	253031108	Meeting Type	Annual
Ticker Symbol	DRNA	Meeting Date	03-Jun-2021
Record Date	06-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Douglas M. Fambrough, III	Management	For	For
1B.	Election of Director: J. Kevin Buchi	Management	For	For
1C.	Election of Director: Stephen Doberstein	Management	For	For
1D.	Election of Director: Martin Freed	Management	For	For
1E.	Election of Director: Patrick M. Gray	Management	For	For
1F.	Election of Director: Stephen J. Hoffman	Management	For	For
1G.	Election of Director: Adam M. Koppel	Management	For	For
1H.	Election of Director: Marc Kozin	Management	For	For
1I.	Election of Director: Cynthia Smith	Management	For	For
2.	To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For
3.	Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement.	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	18-Sep-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Waiver of the procedures for convening meetings and the time limits for the provision of documents and information provided for by the laws and regulations in force	Management	For	For
2.	Review and approval of the delegation of competence to be granted to the CEO in order to decide to increase the share capital with cancellation of the preferential subscription right, by contribution in cash of a maximum amount with EUR 21,206.40 through the issuance of a maximum number of 212,064 ABSA C with a nominal value of ten cents (0.10 ) each and an issue premium of EUR 21.12 each, i.e. an aggregate amount of issue premium of EUR 4,478,791.68 and a total subscription price of EUR 4,499,998.08	Management	For	For
3.	Review and approval of the cancellation of the preferential subscription right of the Shareholders in favor of French and/or foreign investment funds and/or companies	Management	For	For
4.	Review and approval of the delegation of competence to be granted to the CEO to decide the issuance and allocation of a maximum number of 198,014 SO	Management	For	For
5.	Review and approval of the delegation of competence to be granted to the CEO to decide the issuance and allocation of a maximum number of 198,014 BSA2020	Management	For	For
6.	Proposal to cancel the preferential subscription right of the Shareholders with respect to the BSA 2020 in favor of determined categories of beneficiaries	Management	For	For
7.	Review and approval of the delegation of competence granted to the CEO to decide the issuance and allocation of 198,014 AGA2020	Management	For	For
8.	Review and approval of a delegation of competence to be granted to the CEO to decide to increase the share capital with cancellation of the preferential subscription right, by contribution in cash of a maximum amount with EUR 58,906.60 through the issuance of a maximum number of 589,066 ABSA C T1 with a nominal value of ten cents (0.10€) each	Management	For	For
9.	Review and approval of the cancellation of the preferential subscription right of the Shareholders in favor of French and/or foreign investment funds and/or companies	Management	For	For
10.	Amendment of articles 7.4, 14.4 and 14.6 of the Company’s bylaws	Management	For	For
11.	Share capital increase with cancellation of the preferential subscription right in favor of employes pursuant to the conditions of articles L: 3332-18 of the French labor code, in accordance withi the provisions of article L.225-129-6 of the French commercial code	Management	For	For
12.	Powers for formalities	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	15-Oct-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Waiver of the Conditions of Second Tranche Mandatory Exercise	Management	For	For

DYNACURE

Security	N/A	Meeting Type	General Meeting
Ticker Symbol	N/A	Meeting Date	10-Nov-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Waiver of the prior notice period and of the period for provision of the documents pursuant to the laws and regulations in force	Management	For	For
2.	Conversion of the Company into a public limited company with a board of directors (societe anonyme a conseil d’administration)	Management	For	For
3.	Adoption of new restated bylaws of the Company	Management	For	For
4.	Acknowledgement of termination of the terms of offices of the President and all members and censors of the Supervisory Board	Management	For	For
5.	Appointment of the first directors of the Company in its form as a public limited company (societe anonyme)	Management	For	For
6.	Determination of the remuneration allocated to the directors	Management	For	For
7.	Creation of a committee of censors	Management	For	For
8.	Confirmation of the functions of the Company’s statutory auditors	Management	For	For
9.	Provisions relating to the financial accounts of the Company	Management	For	For
10.	Acknowledgement of the conversion of the Company into a public limited company (societe anonyme)	Management	For	For
11.	Review and approval of the delegation of competence to be granted to the Board of Directors to decide the issuance and allocation of a maximumnumber of 323,968 SO	Management	For	For
12.	Review and approval of the delegation of competence to be granted to the Board of Directors to decide the issuance and allocation of a maximum number of 323,968 BSA 2020	Management	For	For
13.	Proposal to cancel the Shareholders’ preferential subscription right with respect to the BSA2020 in favor of determined categories of beneficiaries	Management	For	For
14.	Review and approval of the delegation of competence granted to the Board of Directors to decide the issuance and allocation of 323,968 AGA 2020	Management	For	For
15.	Share capital increae with cancellation of the preferential subscription right in favor of employees pursuant to the conditions of articles L. 3332-18 of the French Labor Code, in accordance with the provisions of article L.225-129-6 of the French Commercial Code	Management	Against	Against
16.	Powers to carry out formalities	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Ordinary General Meeting
Ticker Symbol	N/A	Meeting Date	5-Jan-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Appointment of Mrs. Jean Franchi as a new member of the board of directors	Management	For	For
2.	Determination of the compensation to be allocated to the members of the board of directors	Management	For	For
3.	Powers to carry out formalities	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Combined General Meeting
Ticker Symbol	N/A	Meeting Date	28-Jan-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of annual financial statements for the fiscal year ended December 31, 2020 and discharge of the Chairman of the Board of Directors, the CEO, the Directors and the statutory auditors performance during the past year.	Management	For	For
2.	Allocation of the result for the fiscal year ended December 31, 2020		For	For
3.	Review of the agreements referred to in Articles L 225-38 et seq. of the French Commercial Code	Management	For	For
4.	Renewal/ duration of the terms of office of directors	Management	For	For
5.	Renewal of the terms of the office of observers	Management	For	For
6.	Delegation of autority to the Board of Directors to increase the share capital by issuing ordinary shares, or any securities giving access to the Company’s share capital, with shareholders ’ preferential subscription right	Management	For	For
7.	Delegation of authority to the Board of Directors to increase the share capital by issuing ordinary shares, or any securities giving access to the Company’s share capital, without shareholders’ preferential subscription right, by way of a public offering excluding offerings referred to in article L. 411-2 1 of the French Monetary and Financial Code	Management	For	For
8.	Delegation of authority to the Board of Directors to increase the share capital by ussuing ordinary shares, or any securities giving access to the Company’s share capital, without shareholders’ preferential subscription right, by way of a public offering referred to in article L. 411-2 1 of the French Monetary and Financial Code	Management	For	For
9.	Delegation of authority to the Board of directors to issue shares of the Company and/or other securites, without shareholders’ preferential subscription right, for the benefit of a category of persons meeting certain characteristics	Management	For	For
10.	Delegation of authority to the Board of directors to issue shares of the Company and/or other securites, without shareholders’ preferential subscription right, for the benefit of a category of persons meeting certain characteristics	Management	For	For
11.	Authorization of the Board of directors to increase the number of securities that may be issued as part of a share capital increase carried out pursuant to the delegations referred to in Proposal No. 6 to 10 above, with or without shareholders ’ preferential subscription rights	Management	For	For
12.	Setting the overal limits on the amount of issues to be carried out pursuant to the delegations referred to in Proposal 6-11 above Propoal No. 21 below	Management	For	For
13.	Delegation of authority to the Board of directors to increase the share capital by incorporation of premiums, reserves, profits or other sums allowed to be capitalized	Management	For	For
14.	Delegation of authority to the Board of directors to grant existinf and/or newly issued free shares of the Company to all certain corporate officers of the Company of companies in the Group, in accordance with the provisions of aricles L. 225-197-1 et seq. of the French Commercial Code	Management	For	For
15.	Delegation of authority to the Board of directors to issue share warrants (bons de souscription d’actions), without shareholders’ preferential subscription right, for the benefit of a category of persons meeting certain characteristics.	Management	For	For
16.	Delegation of authority to the Board of directors to grant options to subscribe for new ordinary shares or options to purchase ordinary shares of the Company, pirsuant to the provisions of articles L. 225-177 et seq. of the French Code, to all or certain employees and/or all or certain corporate officers of the Company or companies in the Group, in accordance with the provisions of articles L. 225-180 et seq. of the French Commerial Code	Management	For	For
17.	Delegation of authority to the Board of directors to increase the share capital by issuing ordinary share (in form of American Depository Shares (“ADSs”)) of the Company, without shareholders ’ prefential subscription right, for the benefit of a category of persons meeting certain characteristics under the 2021 Dynacure S.A. Employee Share Purchase Plan (the “ESPP”)	Management	For	For
18.	Setting the overal limits on the amount of issues to be carried out pursuant to the delegations referred to in Proposal 6-11 above Proposals No. 14.15, 16 and 17 above	Management	For	For
19.	Delegation of authority to the Board of directors of the Company to increase the share capital by way of the issue of shares of the Company to participants in a company savings plan (plan d’epargne d’entreprise) established in accordance with articles L. 3332-1 et seq. of the French Labor Code	Management	For	For
20.	Delagation of the authority to the Board of directors to decide on any merger-absorption, split or partial asset contribution	Management	For	For
21.	Delegation of the authority to the Board of directors to increase the share capital by issuing ordinary shares, or any securities giving access to the Company’s share capital, in the context of the merger absorption, split or partial asset contribution decided by the Board of directors pursuant to the twentieth resolution above	Management	For	For
22.	Authoritization to the Board of directors to reduce the Company’s shares capital by canceling shares aquired by the Company	Management	For	For
23.	Delegation of authority to the Board of directors to reduce the share capital by way og buyback of Company shares followed by the cancellation of the repurchased shares	Management	For	For
24.	Ammendment of the article of 6 of the by-laws, subject to the non-retroactive condition precedent of the Form F-1 Effectiveness	Management	For	For
25.	Modification of the form of shares, subject to the non-retroactive precedent of F-1 Effectiveness	Management	For	For
26.	Modification of the form of shares, subject to the non-retroactive precedent of F-1 Effectiveness	Management	For	For
27.	Ammendment of article 13 of the above bylaws of the Company in order to extend the terms of office of the directors to three years, subject to the non-retroactive condition precedent of the Introduction	Management	For	For
28.	Adoption of the new bylaws, subject to the non-retroactive condition precedent of the Introduction	Management	For	For
29.	Powers to carry out formalities	Management	For	For

EXACT SCIENCES CORPORATION

Security	30063P105	Meeting Type	Annual
Ticker Symbol	EXAS	Meeting Date	30-Jun-2021
Record Date	06-May-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Paul Clancy		For	For
	2	Pierre Jacquet		For	For
	3	Daniel Levangie		For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2021.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company’s named executive officers.		Management	For	For

EXELIXIS, INC.

Security	30161Q104	Meeting Type	Annual
Ticker Symbol	EXEL	Meeting Date	26-May-2021
Record Date	29-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Charles Cohen, Ph.D.	Management	For	For
1B.	Election of Director: Carl B. Feldbaum, Esq.	Management	For	For
1C.	Election of Director: Maria C. Freire, Ph.D.	Management	For	For
1D.	Election of Director: Alan M. Garber, M.D., Ph.D.	Management	For	For
1E.	Election of Director: Vincent T. Marchesi, M.D., Ph.D.	Management	For	For
1F.	Election of Director: Michael M. Morrissey, Ph.D.	Management	For	For
1G.	Election of Director: Stelios Papadopoulos, Ph.D.	Management	For	For
1H.	Election of Director: George Poste, DVM, Ph.D., FRS	Management	For	For
1I.	Election of Director: Julie Anne Smith	Management	For	For
1J.	Election of Director: Lance Willsey, M.D.	Management	For	For
1K.	Election of Director: Jack L. Wyszomierski	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For
3.	To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the accompanying Proxy Statement.	Management	For	For

FATE THERAPEUTICS, INC.

Security	31189P102	Meeting Type	Annual
Ticker Symbol	FATE	Meeting Date	02-Jun-2021
Record Date	05-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	R. Hershberg, M.D, Ph.D		For	For
	2	Michael Lee		For	For
	3	W.H. Rastetter, Ph.D.		For	For
2.	To approve the ratification of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.		Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.		Management	For	For
4.	To approve the amendment and restatement of the Company’s Amended and Restated Certificate of Incorporation to increase the amount of authorized common stock from 150,000,000 shares to 250,000,000 shares.		Management	For	For

FORMA THERAPEUTICS HOLDINGS, INC.

Security	34633R104	Meeting Type	Annual
Ticker Symbol	FMTX	Meeting Date	17-Jun-2021
Record Date	20-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Selwyn M. Vickers, M.D.		For	For
	2	Wayne A.I Frederick M.D		For	For
2.	Ratification of the Appointment of Ernst & Young LLP as Forma Therapeutics Holdings, Inc.’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021.		Management	For	For

G1 THERAPEUTICS, INC.

Security	3621LQ109	Meeting Type	Annual
Ticker Symbol	GTHX	Meeting Date	17-Jun-2021
Record Date	20-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	John E. Bailey, Jr.		For	For
	2	Willie A. Deese		For	For
	3	Cynthia L. Schwalm		For	For
2.	An advisory (non-binding) vote to approve executive compensation.		Management	For	For
3.	The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

GALERA THERAPEUTICS, INC.

Security	36338D108	Meeting Type	Annual
Ticker Symbol	GRTX	Meeting Date	16-Jun-2021
Record Date	23-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Lawrence Alleva		For	For
	2	Kevin Lokay		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

GENMAB A S

Security	372303206	Meeting Type	Annual
Ticker Symbol	GMAB	Meeting Date	13-Apr-2021
Record Date	09-Mar-2021

Item		Proposal	Proposed by	Vote	For/Against Management
2.		Presentation and adoption of the audited Annual Report and discharge of Board of Directors and Executive Management.	Management	For	For
3.		Resolution on the distribution of profits as recorded in the adopted Annual Report.	Management	For	For
4.		Advisory vote on the Compensation Report.	Management	For	For
5A.		Re-election of Director: Deirdre P. Connelly	Management	For	For
5B.		Re-election of Director: Pernille Erenbjerg	Management	For	For
5C.	��	Re-election of Director: Rolf Hoffmann	Management	For	For
5D.		Re-election of Director: Dr. Paolo Paoletti	Management	For	For
5E.		Re-election of Director: Jonathan Peacock	Management	For	For
5F.		Re-election of Director: Dr. Anders Gersel Pedersen	Management	For	For
6.		Re-election PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as on auditor.	Management	For	For
7A.		Proposals from the Board of Directors: Approval of the Board of Directors’ remuneration for 2021.	Management	For	For
7B.		Proposals from the Board of Directors: Amendment to Remuneration Policy for Board of Directors and Executive Management (base fee multiplier for Chair and Deputy Chair).	Management	For	For
7C.		Proposals from the Board of Directors: Adoption of amended Remuneration Policy for Board of Directors and Executive Management (certain other changes).	Management	For	For
7D.		Proposals from the Board of Directors: Authorization of the Board of Directors to acquire treasury shares.	Management	For	For
7E.		Proposals from the Board of Directors: Amendment of Article 4A (authorization to issue new shares) and Article 5A (authorization to issue convertible debt) and adoption of a new Article 5B.	Management	For	For
7F.		Proposals from the Board of Directors: Amendment of Article 5 (authorization to issue warrants).	Management	For	For
7G.		Proposals from the Board of Directors: Authorization to hold wholly virtual general meetings.	Management	For	For
8.		Authorization of the Chair of the General Meeting to register resolutions passed by the General Meeting.	Management	For	For

GILEAD SCIENCES, INC.

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	12-May-2021
Record Date	19-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director to serve for the next year: Jacqueline K. Barton, Ph.D.	Management	For	For
1B.	Election of Director to serve for the next year: Jeffrey A. Bluestone, Ph.D.	Management	For	For
1C.	Election of Director to serve for the next year: Sandra J. Horning, M.D.	Management	For	For
1D.	Election of Director to serve for the next year: Kelly A. Kramer	Management	For	For
1E.	Election of Director to serve for the next year: Kevin E. Lofton	Management	For	For
1F.	Election of Director to serve for the next year: Harish Manwani	Management	For	For
1G.	Election of Director to serve for the next year: Daniel P. O’Day	Management	For	For
1H.	Election of Director to serve for the next year: Javier J. Rodriguez	Management	For	For
1I.	Election of Director to serve for the next year: Anthony Welters	Management	For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2021.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.	Shareholder	Against	For

GUARDANT HEALTH, INC.

Security	40131M109	Meeting Type	Annual
Ticker Symbol	GH	Meeting Date	16-Jun-2021
Record Date	19-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director: Helmy Eltoukhy, Ph.D.	Management	For	For
1B.	Election of Class III Director: AmirAli Talasaz, Ph.D.	Management	For	For
1C.	Election of Class III Director: Bahija Jallal, Ph.D.	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as Guardant Health, Inc.’s independent registered public accounting firm for the year ending December 31, 2021.	Management	For	For
3.	Advisory vote to approve named executive officer compensation.	Management	For	For

HERON THERAPEUTICS, INC.

Security	427746102	Meeting Type	Annual
Ticker Symbol	HRTX	Meeting Date	17-Jun-2021
Record Date	20-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director to serve until the 2022 Annual Meeting: Barry Quart, Pharm.D.	Management	For	For
1B.	Election of Director to serve until the 2022 Annual Meeting: Stephen Davis	Management	For	For
1C.	Election of Director to serve until the 2022 Annual Meeting: Craig Johnson	Management	For	For
1D.	Election of Director to serve until the 2022 Annual Meeting: Kimberly Manhard	Management	For	For
1E.	Election of Director to serve until the 2022 Annual Meeting: Christian Waage	Management	For	For
2.	To ratify the appointment of OUM & Co. LLP as our independent registered public accounting firm for the year ending December 31, 2021.	Management	For	For
3.	To approve, on an advisory basis, compensation paid to our Named Executive Officers during the year ended December 31, 2020.	Management	For	For
4.	To amend the Company’s 2007 Amended and Restated Equity Incentive Plan (the “2007 Plan”) to increase the number of shares of common stock authorized for issuance thereunder from 25,800,000 to 27,800,000.	Management	For	For
5.	To amend the Company’s 1997 Employee Stock Purchase Plan, as amended (the “ESPP”) to increase the number of shares of common stock authorized for issuance thereunder from 775,000 to 975,000.	Management	For	For

HORIZON THERAPEUTICS PLC

Security	G46188101	Meeting Type	Annual
Ticker Symbol	HZNP	Meeting Date	29-Apr-2021
Record Date	24-Feb-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: William F. Daniel	Management	For	For
1B.	Election of Class I Director: H. Thomas Watkins	Management	For	For
1C.	Election of Class I Director: Pascale Witz	Management	For	For
2.	Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021 and authorization of the Audit Committee to determine the auditors’ remuneration.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.	Management	For	For
4.	Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.	Management	For	For
5.	Approval of the Amended and Restated 2020 Equity Incentive Plan.	Management	For	For

HOTSPOT THERAPEUTICS, INC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Jun-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Series B tranche 2 milestone waiver	Management	For	For

IDEXX LABORATORIES, INC.

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	12-May-2021
Record Date	19-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Bruce L. Claflin	Management	For	For
1B.	Election of Director: Asha S. Collins, PhD	Management	For	For
1C.	Election of Director: Daniel M. Junius	Management	For	For
1D.	Election of Director: Sam Samad	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year (Proposal Two).	Management	For	For
3.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company’s executive compensation (Proposal Three).	Management	For	For

ILLUMINA, INC.

Security	452327109	Meeting Type	Annual
Ticker Symbol	ILMN	Meeting Date	26-May-2021
Record Date	31-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Caroline D. Dorsa	Management	For	For
1B.	Election of Director: Robert S. Epstein, M.D.	Management	For	For
1C.	Election of Director: Scott Gottlieb, M.D.	Management	For	For
1D.	Election of Director: Gary S. Guthart	Management	For	For
1E.	Election of Director: Philip W. Schiller	Management	For	For
1F.	Election of Director: John W. Thompson	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 2, 2022.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For

INCYTE CORPORATION

Security	45337C102	Meeting Type	Annual
Ticker Symbol	INCY	Meeting Date	26-May-2021
Record Date	29-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Julian C. Baker	Management	For	For
1.2	Election of Director: Jean-Jacques Bienaimé	Management	For	For
1.3	Election of Director: Paul J. Clancy	Management	For	For
1.4	Election of Director: Wendy L. Dixon	Management	For	For
1.5	Election of Director: Jacqualyn A. Fouse	Management	For	For
1.6	Election of Director: Edmund P. Harrigan	Management	For	For
1.7	Election of Director: Katherine A. High	Management	For	For
1.8	Election of Director: Hervé Hoppenot	Management	For	For
2.	Approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.	Management	For	For
3.	Approve amendments to the Company’s Amended and Restated 2010 Stock Incentive Plan.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021.	Management	For	For

INSMED INCORPORATED

Security	457669307	Meeting Type	Annual
Ticker Symbol	INSM	Meeting Date	12-May-2021
Record Date	19-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	David R. Brennan		For	For
	2	Leo Lee		For	For
	3	Carol A. Schafer		For	For
	4	Melvin Sharoky, M.D.		For	For
2.	An advisory vote on the 2020 compensation of our named executive officers.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021.		Management	For	For
4.	Approval of an amendment to the Insmed Incorporated 2019 Incentive Plan.		Management	For	For

INTELLIA THERAPEUTICS, INC.

Security	45826J105	Meeting Type	Annual
Ticker Symbol	NTLA	Meeting Date	23-Jun-2021
Record Date	26-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Fred Cohen, M.D D.Phil		For	For
	2	J. François Formela, MD		For	For
	3	Frank Verwiel, M.D.		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
3.	Approve, on a non-binding advisory basis, the compensation of the named executive officers.		Management	For	For

INTERCEPT PHARMACEUTICALS, INC.

Security	45845P108	Meeting Type	Annual
Ticker Symbol	ICPT	Meeting Date	27-May-2021
Record Date	06-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director to serve until the 2022 Annual Meeting: Paolo Fundarò	Management	For	For
1B.	Election of Director to serve until the 2022 Annual Meeting: Jerome Durso	Management	For	For
1C.	Election of Director to serve until the 2022 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D.	Management	For	For
1D.	Election of Director to serve until the 2022 Annual Meeting: Luca Benatti, Ph.D.	Management	For	For
1E.	Election of Director to serve until the 2022 Annual Meeting: Daniel Bradbury	Management	For	For
1F.	Election of Director to serve until the 2022 Annual Meeting: Keith Gottesdiener, M.D.	Management	For	For
1G.	Election of Director to serve until the 2022 Annual Meeting: Nancy Miller-Rich	Management	For	For
1H.	Election of Director to serve until the 2022 Annual Meeting: Mark Pruzanski, M.D.	Management	For	For
1I.	Election of Director to serve until the 2022 Annual Meeting: Dagmar Rosa-Bjorkeson	Management	For	For
1J.	Election of Director to serve until the 2022 Annual Meeting: Gino Santini	Management	For	For
1K.	Election of Director to serve until the 2022 Annual Meeting: Glenn Sblendorio	Management	For	For
2.	FOR the approval of a one-time stock option exchange program for non-executive employees.	Management	For	For
3.	FOR the approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers.	Management	For	For
4.	Voting on a non-binding, advisory basis, that the stockholder advisory vote on the compensation of the Company’s named executive officers should occur every ONE YEAR.	Management	1 Year	For
5.	FOR the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.	Management	For	For

INTRA-CELLULAR THERAPIES INC

Security	46116X101	Meeting Type	Annual
Ticker Symbol	ITCI	Meeting Date	21-Jun-2021
Record Date	28-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Sir Michael Rawlins, MD		For	For
	2	Joel S. Marcus		For	For
2.	To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock for issuance from 100,000,000 to 175,000,000.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
4.	To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in the proxy statement.		Management	For	For

INVETX, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	30-Mar-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Director	Management	For	For

IONIS PHARMACEUTICALS, INC.

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	02-Jun-2021
Record Date	05-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Brett Monia		For	For
	2	Frederick Muto		For	For
	3	Peter Reikes		For	For
2.	To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under such plan by 6,700,000 shares to an aggregate of 29,700,000 shares and add a fungible share counting ratio.		Management	For	For
3.	To approve, by non-binding vote, executive compensation.		Management	For	For
4.	Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2021 fiscal year.		Management	For	For

IOVANCE BIOTHERAPEUTICS, INC.

Security	462260100	Meeting Type	Annual
Ticker Symbol	IOVA	Meeting Date	11-Jun-2021
Record Date	19-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Iain Dukes, D. Phil		For	For
	2	Maria Fardis, Ph.D, MBA		For	For
	3	Athena Countouriotis MD		For	For
	4	Ryan Maynard		For	For
	5	Merrill A. McPeak		For	For
	6	Wayne P. Rothbaum		For	For
	7	Michael Weiser MD Ph.D		For	For
2.	To approve, by non-binding advisory vote, the compensation of our named executive officers.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For

JAZZ PHARMACEUTICALS PLC

Security	G50871105	Meeting Type	Annual
Ticker Symbol	JAZZ	Meeting Date	30-Jul-2020
Record Date	03-Jun-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Bruce C. Cozadd	Management	For	For
1B.	Election of Director: Heather Ann McSharry	Management	For	For
1C.	Election of Director: Anne O’Riordan	Management	For	For
1D.	Election of Director: Rick E Winningham	Management	For	For
2.	To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2020 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the auditors’ remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc’s named executive officers as disclosed in the proxy statement.	Management	For	For
4.	To approve an amendment and restatement of Jazz Pharmaceuticals plc’s Amended and Restated 2007 Non- Employee Directors Stock Award Plan in order to, among other things, increase the number of ordinary shares authorized for issuance by 500,000 shares.	Management	For	For
5.	To approve a capital reduction and creation of distributable reserves under Irish law.	Management	For	For

JOUNCE THERAPEUTICS, INC.

Security	481116101	Meeting Type	Annual
Ticker Symbol	JNCE	Meeting Date	18-Jun-2021
Record Date	21-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	J. Duncan Higgons		For	For
	2	R Iannone, M.D, M.S.C.E		For	For
	3	Luisa Salter-Cid, Ph.D.		For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

KARUNA THERAPEUTICS, INC.

Security	48576A100	Meeting Type	Annual
Ticker Symbol	KRTX	Meeting Date	16-Jun-2021
Record Date	19-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Christopher Coughlin	Management	For	For
1B.	Election of Director: James Healy, M.D., Ph.D.	Management	For	For
1C.	Election of Director: Jeffrey Jonas, M.D.	Management	For	For
2.	Proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

KURA ONCOLOGY, INC.

Security	50127T109	Meeting Type	Annual
Ticker Symbol	KURA	Meeting Date	22-Jun-2021
Record Date	23-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Troy E. Wilson, PhD JD		For	For
	2	Faheem Hasnain		For	For
2.	To ratify selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For
3.	Approval, on an advisory basis, of the compensation of our Named Executive Officers during the year ended December 31, 2020.		Management	For	For

MADRIGAL PHARMACEUTICALS INC.

Security	558868105	Meeting Type	Annual
Ticker Symbol	MDGL	Meeting Date	17-Jun-2021
Record Date	26-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Rebecca Taub, M.D.		For	For
	2	Fred B. Craves, Ph.D.		For	For
2.	To approve our amended 2015 Stock Plan.		Management	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
4.	Advisory vote on compensation of named executive officers.		Management	For	For
5.	In their discretion, the proxies are authorized to vote and act upon any other matters which may properly come before the meeting or any adjournment or postponement thereof.		Management	For	For

MEDPACE HOLDINGS, INC.

Security	58506Q109	Meeting Type	Annual
Ticker Symbol	MEDP	Meeting Date	14-May-2021
Record Date	18-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Fred B. Davenport, Jr.		For	For
	2	C. P. McCarthy III		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2021 Annual Meeting.		Management	For	For

MENLO THERAPEUTICS

Security	586858102	Meeting Type	Annual
Ticker Symbol	MNLO	Meeting Date	03-Aug-2020
Record Date	10-Jun-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Sharon Barbari		For	For
	2	Rex Bright		For	For
2.	To ratify the selection, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For
3.	To approve and adopt amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Reverse Stock Split Amendment”) to (i) effect a reverse stock split of Company’s common stock on or before August 3, 2021 at a ratio ranging from 1-for-2 shares up to a ratio of 1-for-7 shares, which ratio will be selected by the Company’s Board of Directors and set forth in a public announcement (the “Reverse Stock Split”), & (ii) reduce number of authorized shares of Company’s common stock by a corresponding ratio (“Authorized Share Reduction”).		Management	For	For

MEREO BIOPHARMA GROUP PLC

Security	589492107	Meeting Type	Annual
Ticker Symbol	MREO	Meeting Date	27-May-2021
Record Date	15-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	That the annual report and accounts for the financial year ended 31 December 2020, together with the directors’ report and independent auditor’s report thereon, be received and adopted.	Management	For	For
2.	That Ernst & Young LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next Annual General Meeting at which the Company’s annual report and accounts are presented.	Management	For	For
3.	That the directors of the Company be authorised to determine Ernst & Young LLP’s remuneration.	Management	For	For
4.	That the directors’ remuneration report (excluding the directors’ remuneration policy, set out on pages 39 to 61 of the directors’ remuneration report), as set out in the Company’s annual report and accounts for the financial year ended 31 December 2020, be approved.	Management	For	For
5.	That the directors’ remuneration policy, as set out on pages 42 to 51 of the directors’ remuneration report, which takes effect immediately after the end of AGM, be approved.	Management	For	For
6.	That Dr. Jeremy Bender be re-appointed as a director of the Company.	Management	For	For
7.	That Dr. Brian Schwartz be re-appointed as a director of the Company.	Management	For	For
8.	That Dr. Peter Fellner be re-appointed as a director of the Company.	Management	For	For
9.	That Dr. Denise Scots-Knight be re-appointed as a director of the Company.	Management	For	For
10.	That Peter Bains be re-appointed as a director of the Company.	Management	For	For
11.	That Dr. Anders Ekblom be re-appointed as a director of the Company.	Management	For	For
12.	That Kunal Kashyap be re-appointed as a director of the Company.	Management	For	For

MIRATI THERAPEUTICS, INC.

Security	60468T105	Meeting Type	Annual
Ticker Symbol	MRTX	Meeting Date	12-May-2021
Record Date	15-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Charles M. Baum		For	For
	2	Bruce L.A. Carter		For	For
	3	Julie M. Cherrington		For	For
	4	Aaron I. Davis		For	For
	5	Henry J. Fuchs		For	For
	6	Michael Grey		For	For
	7	Faheem Hasnain		For	For
	8	Craig Johnson		For	For
	9	Maya Martinez-Davis		For	For
	10	Shalini Sharp		For	For
2.	To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For
4.	To approve our Amended and Restated 2013 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under such plan by 2,500,000 shares.		Management	For	For

MODERNA, INC.

Security	60770K107	Meeting Type	Annual
Ticker Symbol	MRNA	Meeting Date	28-Apr-2021
Record Date	01-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Robert Langer, Sc.D.		For	For
	2	Elizabeth Nabel, M.D.		For	For
	3	Elizabeth Tallett		For	For
2.	To cast a non-binding, advisory vote to approve the compensation of our named executive officers.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our registered independent public accounting firm for the year ending December 31, 2021.		Management	For	For

MOLECULAR TEMPLATES, INC.

Security	608550109	Meeting Type	Annual
Ticker Symbol	MTEM	Meeting Date	03-Jun-2021
Record Date	07-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Jonathan Lanfear	Management	For	For
1.2	Election of Director: Scott Morenstein	Management	For	For
1.3	Election of Director: Corsee Sanders, Ph.D.	Management	For	For
2.	Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For
3.	Approve on an advisory basis the compensation of the Company’s named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For

MORPHIC HOLDING INC

Security	61775R105	Meeting Type	Annual
Ticker Symbol	MORF	Meeting Date	16-Jun-2021
Record Date	21-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Gustav Christensen		For	For
	2	Martin Edwards		For	For
	3	Susannah Gray		For	For
	4	Amir Nashat		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

NEKTAR THERAPEUTICS

Security	640268108	Meeting Type	Annual
Ticker Symbol	NKTR	Meeting Date	10-Jun-2021
Record Date	12-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Jeff Ajer	Management	For	For
1B.	Election of Director: Robert B. Chess	Management	For	For
1C.	Election of Director: Roy A. Whitfield	Management	For	For
2.	To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,000,000 shares.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For
4.	To approve a non-binding advisory resolution regarding our executive compensation (a “say-on-pay” vote).	Management	For	For

NEUROCRINE BIOSCIENCES, INC.

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	19-May-2021
Record Date	23-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	William H Rastetter PhD		For	For
	2	George J. Morrow		For	For
	3	Leslie V. Norwalk		For	For
2.	Advisory vote to approve the compensation paid to the Company’s named executive officers.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

NKARTA INC

Security	65487U108	Meeting Type	Annual
Ticker Symbol	NKTX	Meeting Date	11-Jun-2021
Record Date	16-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Tiba Aynechi, Ph.D.		For	For
	2	Fouad Azzam, Ph.D.		For	For
	3	Paul Hastings		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending December 31, 2021.		Management	For	For

NOVAVAX, INC.

Security	670002401	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	17-Jun-2021
Record Date	20-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director to serve for a three-year term expiring at the 2024 Annual Meeting: Richard H. Douglas, Ph.D.	Management	For	For
1B.	Election of Class II Director to serve for a three-year term expiring at the 2024 Annual Meeting: Margaret G. McGlynn, R. Ph.	Management	For	For
1C.	Election of Class II Director to serve for a three-year term expiring at the 2024 Annual Meeting: David M. Mott	Management	For	For
2.	The approval, on an advisory basis, of the compensation paid to our Named Executive Officers.	Management	For	For
3.	Amendment and restatement of the Amended and Restated Novavax, Inc. 2015 Stock Plan to increase the number of shares of Common Stock available for issuance thereunder by 1,500,000 shares.	Management	For	For
4.	Ratification of certain April 2020 equity awards.	Management	For	For
5.	Ratification of certain June 2020 equity awards.	Management	For	For
6.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Annual General Meeting
Ticker Symbol	N/A	Meeting Date	24-Jun-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the Annual Report including Financial Statements 2020	Management	For	For
2.	Allocation of Balance Sheet Results 2020	Management	For	For
3.	Discharge to Members of the Board of Directors and the Management	Management	For	For
4.	Re-Election of the Members of the Board of Directors	Management	For	For
5.	Re-Election of the Auditors PricewaterhouseCoopers SA	Management	For	For

OVID THERAPEUTICS INC.

Security	690469101	Meeting Type	Annual
Ticker Symbol	OVID	Meeting Date	10-Jun-2021
Record Date	15-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I director to hold office until the 2024 Annual Meeting: Barbara Duncan	Management	For	For
2.	Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Security	69404D108	Meeting Type	Annual
Ticker Symbol	PACB	Meeting Date	04-Aug-2020
Record Date	15-Jun-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election Of Class I Director: Christian O. Henry	Management	For	For
1.2	Election Of Class I Director: John F. Milligan, Ph.D.	Management	For	For
1.3	Election Of Class I Director: Lucy Shapiro, Ph.D	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020.	Management	For	For
3.	Advisory approval of the Company’s executive compensation.	Management	For	For
4.	Approval of the Company’s 2020 Equity Incentive Plan.	Management	For	For

PERSONALIS, INC.

Security	71535D106	Meeting Type	Annual
Ticker Symbol	PSNL	Meeting Date	14-May-2021
Record Date	19-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director: John West	Management	For	For
1.2	Election of Class II Director: Alan Colowick, M.D.	Management	For	For
2.	Ratification of the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.	Management	For	For

PIERIS PHARMACEUTICALS, INC.

Security	720795103	Meeting Type	Annual
Ticker Symbol	PIRS	Meeting Date	25-Jun-2021
Record Date	27-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Peter Kiener		For	For
	2	Christopher Kiritsy		For	For
2.	Approve the Amendment to the Company’s 2020 Employee, Director and Consultant Equity Incentive Plan.		Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
4.	Approve, on non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.		Management	For	For

PRA HEALTH SCIENCES, INC.

Security	69354M108	Meeting Type	Special
Ticker Symbol	PRAH	Meeting Date	15-Jun-2021
Record Date	26-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger, dated as of February 24, 2021, by and among ICON plc (“ICON”), PRA Health Sciences, Inc. (“PRA”), ICON US Holdings Inc., a wholly owned subsidiary of ICON (“US HoldCo”), and Indigo Merger Sub, Inc., a wholly owned subsidiary of ICON and US HoldCo (such agreement, as it may be amended from time to time, the “merger agreement” and such proposal, the “PRA merger agreement proposal”).	Management	For	For
2.	To approve, on an advisory (non-binding) basis, the executive officer compensation that will or may be paid to PRA’s named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement (the “PRA compensation proposal”).	Management	For	For
3.	To approve the adjournment of the PRA stockholder meeting to solicit additional proxies if there are not sufficient votes at the time of the PRA stockholder meeting to approve the PRA merger agreement proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to PRA stockholders (the “PRA adjournment proposal”).	Management	For	For

PRAXIS PRECISION MEDICINES, INC.

Security	74006W108	Meeting Type	Annual
Ticker Symbol	PRAX	Meeting Date	08-Jun-2021
Record Date	16-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Dean Mitchell	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as Praxis Precision Medicines, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

PRECISION BIOSCIENCES, INC.

Security	74019P108	Meeting Type	Annual
Ticker Symbol	DTIL	Meeting Date	10-May-2021
Record Date	15-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stanley R Frankel, M.D.		For	For
	2	Derek Jantz, Ph.D.		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Precision’s independent registered public accounting firm for 2021.		Management	For	For

QUOTIENT LIMITED

Security	G73268107	Meeting Type	Annual
Ticker Symbol	QTNT	Meeting Date	29-Oct-2020
Record Date	31-Aug-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Franz Walt		For	For
	2	Isabelle Buckle		For	For
	3	Frederick Hallsworth		For	For
	4	Catherine Larue		For	For
	5	Brian McDonough		For	For
	6	Heino von Prondzynski		For	For
	7	Zubeen Shroff		For	For
	8	John Wilkerson		For	For
9.	A non-binding, advisory vote on the compensation paid to the Company’s named executive officers, as described in the “Compensation Discussion and Analysis” section of the Company’s proxy statement and the related compensation tables, notes and narrative discussion.		Management	For	For
10.	A non-binding, advisory vote on the frequency of future advisory votes to approve the compensation paid to the Company’s named executed officers.		Management	1 Year	For
11.	Vote to approve the Third Amended and Restated 2014 Plan, which reflects amendments to the 2014 Plan to (a) increase the number of ordinary shares authorized for issuance by 750,000 shares and to increase the maximum number of shares that may be issued upon the exercise of incentive stock options by 750,000 shares and (b) modify the “evergreen” provision		Management	For	For
12.	Proposal to re-appoint Ernst & Young LLP as the Company’s auditors from the conclusion of this meeting until the next Annual General Meeting of the Company to be held in 2021, to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm and to authorize the directors to determine the fees to be paid to the auditors.		Management	For	For

RALLYBIO HOLDINGS, LLC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	28-Aug-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Board of Managers	Management	For	For

RALLYBIO HOLDINGS, LLC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	22-Oct-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Size of the Board of Managers and New Director	Management	For	For

RALLYBIO HOLDINGS, LLC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	14-Jan-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Equity Pool	Management	For	For

RALLYBIO HOLDINGS, LLC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Jan-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Clinical Trial & Assay Development Master Services Agreement	Management	For	For

RALLYBIO HOLDINGS, LLC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Feb-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Creation of Subsidiaries	Management	For	For
2.	Master Services Agreement with PPD Development	Management	For	For

REATA PHARMACEUTICALS, INC.

Security	75615P103	Meeting Type	Annual
Ticker Symbol	RETA	Meeting Date	10-Jun-2021
Record Date	15-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	William D. McClellan Jr		For	For
	2	William E. Rose		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

REGENERON PHARMACEUTICALS, INC.

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	11-Jun-2021
Record Date	13-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: N. Anthony Coles, M.D.	Management	For	For
1B.	Election of Director: Arthur F. Ryan	Management	For	For
1C.	Election of Director: George L. Sing	Management	For	For
1D.	Election of Director: Marc Tessier-Lavigne, Ph.D.	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

SAGE THERAPEUTICS, INC.

Security	78667J108	Meeting Type	Annual
Ticker Symbol	SAGE	Meeting Date	10-Jun-2021
Record Date	13-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Elizabeth Barrett		For	For
	2	Geno Germano		For	For
	3	Steven Paul, M.D.		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For
3.	To hold a non-binding advisory vote to approve the compensation paid to our named executive officers.		Management	For	For

SAREPTA THERAPEUTICS INC.

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	03-Jun-2021
Record Date	09-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to hold office until the 2023 Annual meeting: Richard J. Barry	Management	For	For
1.2	Election of Class II Director to hold office until the 2023 Annual meeting: M. Kathleen Behrens, Ph.D.	Management	For	For
1.3	Election of Class II Director to hold office until the 2023 Annual meeting: Claude Nicaise, M.D.	Management	For	For
2.	To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.	Management	For	For
3.	To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2021.	Management	For	For

SCHOLAR ROCK HOLDING CORPORATION

Security	80706P103	Meeting Type	Annual
Ticker Symbol	SRRK	Meeting Date	27-May-2021
Record Date	29-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey S. Flier, M.D.		For	For
	2	Amir Nashat, Sc.D.		For	For
	3	Akshay Vaishnaw MD, PhD		For	For
2.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

SEAGEN INC.

Security	81181C104	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	14-May-2021
Record Date	18-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director for term expiring in 2024: Felix J. Baker, Ph.D.	Management	For	For
1B.	Election of Class II Director for term expiring in 2024: Clay B. Siegall, Ph.D	Management	For	For
1C.	Election of Class II Director for term expiring in 2024: Nancy A. Simonian, M.D.	Management	For	For
2.	Approve, on an advisory basis, the compensation of Seagen’s named executive officers as disclosed in the accompanying proxy statement.	Management	For	For
3.	Ratify the appointment of PricewaterhouseCoopers LLP as Seagen’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

SPECTRUM PHARMACEUTICALS, INC.

Security	84763A108	Meeting Type	Annual
Ticker Symbol	SPPI	Meeting Date	17-Jun-2021
Record Date	20-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: William L. Ashton	Management	For	For
1.2	Election of Director: Nora E. Brennan	Management	For	For
1.3	Election of Director: Seth H.Z. Fischer	Management	For	For
1.4	Election of Director: Joseph W. Turgeon	Management	For	For
1.5	Election of Director: Jeffrey L. Vacirca	Management	For	For
1.6	Election of Director: Dolatrai M. Vyas	Management	For	For
1.7	Election of Director: Bernice R. Welles	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.	Management	For	For
3.	To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

SUTRO BIOPHARMA, INC.

Security	869367102	Meeting Type	Annual
Ticker Symbol	STRO	Meeting Date	03-Jun-2021
Record Date	12-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Joseph Lobacki		For	For
	2	Daniel Petree		For	For
	3	Shalini Sharp		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

SYNEOS HEALTH, INC.

Security	87166B102	Meeting Type	Annual
Ticker Symbol	SYNH	Meeting Date	12-May-2021
Record Date	19-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Thomas Allen	Management	For	For
1B.	Election of Director: Linda A. Harty	Management	For	For
1C.	Election of Director: Alistair Macdonald	Management	For	For
2.	To approve on an advisory (nonbinding) basis our executive compensation.	Management	For	For
3.	To ratify the appointment of the Company’s independent auditors Deloitte & Touche LLP.	Management	For	For

THERAVANCE BIOPHARMA, INC.

Security	G8807B106	Meeting Type	Annual
Ticker Symbol	TBPH	Meeting Date	27-Apr-2021
Record Date	01-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Eran Broshy	Management	For	For
1.2	Election of Director: Laurie Smaldone Alsup	Management	For	For
1.3	Election of Director: Burton G. Malkiel	Management	For	For
2.	Approve a non-binding proposal to ratify the appointment of Deepika R. Pakianathan to serve as a Class III member of the board of directors until the annual general meeting held in 2023 and until her successor is duly elected and qualified.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

TRAVERE THERAPEUTICS INC.

Security	89422G107	Meeting Type	Annual
Ticker Symbol	TVTX	Meeting Date	14-May-2021
Record Date	23-Mar-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stephen Aselage		For	For
	2	Roy Baynes		For	For
	3	Suzanne Bruhn		For	For
	4	Timothy Coughlin		For	For
	5	Eric Dube		For	For
	6	Gary Lyons		For	For
	7	Jeffrey Meckler		For	For
	8	John Orwin		For	For
	9	Sandra Poole		For	For
	10	Ron Squarer		For	For
2.	To approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000.		Management	For	For
3.	To approve the Company’s 2018 Equity Incentive Plan, as amended, to, among other items, increase the number of shares of common stock authorized for issuance thereunder by 3,200,000 shares.		Management	For	For
4.	To approve, on an advisory basis, the compensation of the Company’s named executive officers.		Management	For	For
5.	To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.		Management	For	For

TRILLIUM THERAPEUTICS INC.

Security	89620X506	Meeting Type	Annual and Special Meeting
Ticker Symbol	TRIL	Meeting Date	08-Jun-2021
Record Date	19-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Luke Beshar		For	For
	2	Michael Kamarck		For	For
	3	Paul Walker		For	For
	4	Paolo Pucci		For	For
	5	Jan Skvarka		For	For
	6	Helen Tayton-Martin		For	For
	7	Scott Myers		For	For
2	To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors.		Management	For	For
3	To consider and if deemed appropriate, act upon an advisory vote on the compensation of the Corporation’s named executive officers, the full text of the resolution is set forth in the management information circular and proxy statement (the “Circular”) prepared in connection with the Meeting.		Management	For	For
4	To consider and if deemed appropriate, act upon an advisory vote on the frequency of future advisory votes on the compensation of the Corporation’s named executed officers, the full text of the resolution is set forth in the Circular.		Management	1 Year	For

TURNING POINT THERAPEUTICS, INC.

Security	90041T108	Meeting Type	Annual
Ticker Symbol	TPTX	Meeting Date	02-Jun-2021
Record Date	07-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Simeon J. George, M.D		For	For
	2	Carol Gallagher Pharm.D		For	For
2.	Advisory approval of the compensation of our named executive officers, as disclosed in the Proxy Statement in accordance with SEC rules.		Management	For	For
3.	Advisory indication of the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.		Management	1 Year	For
4.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For

ULTRAGENYX PHARMACEUTICAL INC.

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	24-Jun-2021
Record Date	26-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Deborah Dunsire, M.D.	Management	For	For
1B.	Election of Director: Michael Narachi	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Special
Ticker Symbol	QURE	Meeting Date	01-Dec-2020
Record Date	03-Nov-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Appointment of Robert Gut, M.D., Ph.D. as a non- executive director.	Management	For	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	16-Jun-2021
Record Date	19-May-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2020 Dutch statutory annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board for their management.	Management	For	For
3.	Reappointment of David Meek as non-executive director.	Management	For	For
4.	Reappointment of Paula Soteropoulos as non-executive director.	Management	For	For
5.	Approval of the Amendment to the 2014 Restated Plan.	Management	For	For
6.	Resolution to reauthorize the Board to issue ordinary shares and options.	Management	For	For
7.	Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares.	Management	For	For
8.	Authorization of the Board to repurchase ordinary shares.	Management	For	For
9.	Resolution to appoint KPMG as external auditor of the Company for the 2021 financial year.	Management	For	For
10.	Approval of the Amendment to the Articles of Incorporation.	Management	For	For
11.	To approve, on an advisory basis, the compensation of the named executive officers of the Company.	Management	For	For

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	25-Jun-2021
Record Date	30-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Katherine Klein	Management	For	For
1B.	Election of Director: Ray Kurzweil	Management	For	For
1C.	Election of Director: Linda Maxwell	Management	For	For
1D.	Election of Director: Martine Rothblatt	Management	For	For
1E.	Election of Director: Louis Sullivan	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2021.	Management	For	For

VECTIVBIO HOLDING AG

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Aug-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Constitution of the meeting	Management	For	For
2.	Approval of the ordinary capital increase	Management	For	For
3	Amendment of authorized share capital for ordinary shares pursuant to Article 3a of the current articles of association (new Article 3b of the articles of association)	Management	For	For
4	Creation of authorized share capital for A preferred shares (new Article 3a of the articles of association)	Management	For	For
5	Amendment of conditional share capital for participation programs pursuant to Article 3b of the current articles of association (new Article 3c of the articles of association)	Management	For	For
6	Partial amendment of the articles of association	Management	For	For
7	Election of new members of the board of directors of the Company	Management	For	For

VECTIVBIO HOLDING AG

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Oct-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Constitution of the meeting	Management	For	For
2	Increase of authorized share capital for A preferred shares	Management	For	For
3	Election of new member of the board of directors of the company	Management	For	For

VECTIVBIO HOLDING AG

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	18-Feb-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Proxy for EGMs	Management	For	For
1.1	Constitution of the meeting and appointment of chair	Management	For	For
1.2	Reverse share spllit	Management	For	For
1.3	Ordinary share capital increase due to the reverse share split	Management	For	For
1.4	Amendment of the articles of association due to the reverse share split	Management	For	For
1.5	Conversion of series A preferred shares into ordinary shares	Management	For	For
1.6	If the shareholder holds any series A preferred shares: special assembly of preferred shareholders of series A preferred shares regarding the conversion of series A preferred shares into ordinary shares	Management	For	For
1.7	Cancellation of the authorized capital for series A preferred shares	Management	For	For
1.8	Ordinary share capital increase (IPO Capital increase)	Management	For	For
1.9	Amendment of the authorized capital for ordinary shares	Management	For	For
1.1	Amendment of the conditional capital for participation programs	Management	For	For
1.11	Amendment of the conditional capital for financing, acquisitions and other purposes	Management	For	For
1.12	General amendment of the articles of association	Management	For	For
1.13	Approval of any financial statements or the allocation or re-allocation of profits, losses and reserves for purposes of the IPO	Management	For	For
1.14	Approval of post-IPO equity incentive plans and Board, executive, employee or consultant compensation	Management	For	For
1.15	Election of new members of the Board	Management	For	For
1.16	Further resolutions in connection with the IPO, including any of the resolutions set forth in article 22(d) of the Shareholders’ Agreement and any other resolution as may be required or useful in order to implement and complete the IPO	Management	For	For
2	Waiver of and Proxy to Waive Subscription Rights	Management	For	For
3	Acceptance of Additional Shares in Connection with the Reverse Share Split	Management	For	For
4	General Provisions	Management	For	For

VECTIVBIO

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	18-Feb-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Constitution of the meeting and appointment of chair	Management	For	For
2	Approval of the statutory annual financial statements and the consolidated financial statements of the Company for the financial year ended December 31, 2020	Management	For	For
3	Approval of the appropriation of the financial result 2020	Management	For	For
4	Approval of granting discharge to the members of the board of directors and the persons entrusted with the management from liability	Management	For	For
5	Election and re-election of the members of the board of directors	Management	For	For
6	Re-election of the auditors	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Special
Ticker Symbol	VRNA	Meeting Date	18-Dec-2020
Record Date	06-Nov-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt new Articles of Association	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Annual
Ticker Symbol	VRNA	Meeting Date	27-Apr-2021
Record Date	12-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Dr. David Ebsworth as a director of the Company.	Management	For	For
2.	To re-elect Dr. Martin Edwards as a director of the Company.	Management	For	For
3.	To re-elect Dr. Sven Anders Ullman as a director of the Company.	Management	For	For
4.	To re-elect Lisa Deschamps as a director of the Company.	Management	For	For
5.	To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended 31 December 2020.	Management	For	For
6.	To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended 31 December 2020.	Management	For	For
7.	To receive and approve the U.K. Directors’ Remuneration Policy.	Management	For	For
8.	To appoint PricewaterhouseCoopers LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.	Management	For	For
9.	To authorize the Audit and Risk Committee to determine the auditor’s remuneration for the year ending December 31, 2021.	Management	For	For
10.	To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of GBP24,415,222.30.	Management	For	For
11.	To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Companies Act does not apply to any such allotment.	Management	For	For

VERTEX PHARMACEUTICALS INCORPORATED

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	19-May-2021
Record Date	25-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Sangeeta Bhatia	Management	For	For
1B.	Election of Director: Lloyd Carney	Management	For	For
1C.	Election of Director: Alan Garber	Management	For	For
1D.	Election of Director: Terrence Kearney	Management	For	For
1E.	Election of Director: Reshma Kewalramani	Management	For	For
1F.	Election of Director: Yuchun Lee	Management	For	For
1G.	Election of Director: Jeffrey Leiden	Management	For	For
1H.	Election of Director: Margaret McGlynn	Management	For	For
1I.	Election of Director: Diana McKenzie	Management	For	For
1J.	Election of Director: Bruce Sachs	Management	For	For
2.	Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2021.	Management	For	For
3.	Advisory vote to approve named executive officer compensation.	Management	For	For
4.	Shareholder proposal, if properly presented at the meeting, regarding a report on lobbying activities.	Shareholder	Against	For
5.	Shareholder proposal, if properly presented at the meeting, regarding a report on political spending.	Shareholder	Against	For

VIR BIOTECHNOLOGY, INC.

Security	92764N102	Meeting Type	Annual
Ticker Symbol	VIR	Meeting Date	20-May-2021
Record Date	22-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director: Robert Nelsen	Management	For	For
1B.	Election of Class II Director: Robert Perez	Management	For	For
1C.	Election of Class II Director: Phillip Sharp, Ph.D.	Management	For	For
2.	Advisory vote on the frequency of solicitation of advisory stockholder approval of executive compensation.	Management	1 Year	For
3.	Ratification of selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.	Management	For	For

WAVE LIFE SCIENCES LTD.

Security	Y95308105	Meeting Type	Annual
Ticker Symbol	WVE	Meeting Date	12-Aug-2020
Record Date	17-Jun-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Paul B. Bolno, M.D., MBA	Management	For	For
1B.	Election of Director: Mark H. N. Corrigan, M.D.	Management	For	For
1C.	Election of Director: Christian Henry	Management	For	For
1D.	Election of Director: Peter Kolchinsky, Ph.D.	Management	For	For
1E.	Election of Director: Amy Pott	Management	For	For
1F.	Election of Director: Adrian Rawcliffe	Management	For	For
1G.	Election of Director: Ken Takanashi	Management	For	For
1H.	Election of Director: Aik Na Tan	Management	For	For
1I.	Election of Director: Gregory L. Verdine, Ph.D.	Management	For	For
1J.	Election of Director: Heidi L. Wagner, J.D.	Management	For	For
2.	To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2020, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2021 Annual General Meeting of Shareholders.	Management	For	For
3.	To approve the Company’s payment of cash and equity- based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the proxy statement.	Management	For	For
4.	To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.	Management	For	For
5.	To approve by a non-binding advisory vote the compensation of our named executive officers as disclosed in the proxy statement.	Management	For	For

XENON PHARMACEUTICALS INC

Security	98420N105	Meeting Type	Annual
Ticker Symbol	XENE	Meeting Date	03-Jun-2021
Record Date	08-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Simon Pimstone		For	For
	2	Mohammad Azab		For	For
	3	Steven Gannon		For	For
	4	Elizabeth Garofalo		For	For
	5	Michael Hayden		For	For
	6	Patrick Machado		For	For
	7	Ian Mortimer		For	For
	8	Gary Patou		For	For
	9	Dawn Svoronos		For	For
2.	Approve, on an advisory basis, the compensation of the Corporation’s named executive officers.		Management	For	For
3.	Appointment of KPMG LLP as Auditor.		Management	For	For
4.	Authorizing the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the Auditor.		Management	For	For

Y-MABS THERAPEUTICS, INC.

Security	984241109	Meeting Type	Annual
Ticker Symbol	YMAB	Meeting Date	10-Jun-2021
Record Date	16-Apr-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Thomas Gad		For	For
	2	Claus J. Møller-San P.		For	For
	3	J. Wedell-Wedellsborg		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.		Management	For	For
3.	To approve, on a non-binding advisory vote basis, the compensation of the Company’s named executive officers.		Management	For	For
4.	To approve, on a non-binding advisory vote basis, whether future stockholder advisory votes on the compensation of the Company’s named executive officers will occur every 1, 2 or 3 years.		Management	1 Year	For

ZAI LAB LTD

Security	98887Q104	Meeting Type	Special
Ticker Symbol	ZLAB	Meeting Date	04-Sep-2020
Record Date	07-Aug-2020

Item	Proposal	Proposed by	Vote	For/Against Management
O1.	AS AN ORDINARY RESOLUTION: That the shareholders of the Company hereby authorize, approve, and confirm with immediate effect that the authorized share capital of the Company be increased to US$30,000 divided into 500,000,000 shares of a nominal or par value of US$0.00006.	Management	For	For
S2.	AS A SPECIAL RESOLUTION: That, in connection with the increase in share capital, the shareholders of the Company hereby authorize, approve, and confirm with immediate effect that the Fourth Amended and Restated Memorandum of Association of the Company be replaced in its entirety with the consolidated version as tabled at the Meeting and as attached to the notice of the Extraordinary General Meeting.	Management	For	For

ZAI LAB LTD

Security	98887Q104	Meeting Type	Annual
Ticker Symbol	ZLAB	Meeting Date	24-Jun-2021
Record Date	27-Apr-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	A special resolution to consider and approve amending and restating the Fourth Amended and Restated Articles of Association of Zai Lab Limited, or the Current Articles, to provide for the annual election of each of the Company’s directors.	Management	For	For
2.	A special resolution to consider and approve amending and restating the Current Articles to reflect changes required or recommended by The Stock Exchange of Hong Kong Limited.	Management	For	For
3.	A special resolution to consider and approve that, conditional upon the approval of special resolutions 1 and 2, the Current Articles be amended, restated and replaced in their entirety by the Fifth Amended and Restated Articles of Association in the form attached to the proxy statement as Exhibit A.	Management	For	For
4.	An ordinary resolution to ratify the selection of Deloitte Touche Tohmatsu Certified Public Accountants LLP and Deloitte Touche Tohmatsu as the Company’s independent auditors for the fiscal year ending December 31, 2021.	Management	For	For

ZOGENIX, INC.

Security	98978L204	Meeting Type	Annual
Ticker Symbol	ZGNX	Meeting Date	27-May-2021
Record Date	29-Mar-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: James B. Breitmeyer, M.D., Ph.D.	Management	For	For
1B.	Election of Director: Stephen J. Farr, Ph.D.	Management	For	For
1C.	Election of Director: Mary E. Stutts	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021.	Management	For	For
3.	To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For
4.	Approval of an amendment and restatement to our 2010 Equity Incentive Plan.	Management	Against	Against
5.	Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000.	Management	For	For

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)		Tekla Life Sciences Investors
By (Signature and Title)*
			/s/ Daniel R. Omstead
			(Daniel R. Omstead, President)
Date	8/19/21

*Print the name and title of each signing officer under his or her signature.

2